JP2010540657A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540657A5
JP2010540657A5 JP2010528161A JP2010528161A JP2010540657A5 JP 2010540657 A5 JP2010540657 A5 JP 2010540657A5 JP 2010528161 A JP2010528161 A JP 2010528161A JP 2010528161 A JP2010528161 A JP 2010528161A JP 2010540657 A5 JP2010540657 A5 JP 2010540657A5
Authority
JP
Japan
Prior art keywords
patient
antigen
antibody
psma
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540657A (ja
JP5951929B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/078742 external-priority patent/WO2009046294A2/en
Publication of JP2010540657A publication Critical patent/JP2010540657A/ja
Publication of JP2010540657A5 publication Critical patent/JP2010540657A5/ja
Application granted granted Critical
Publication of JP5951929B2 publication Critical patent/JP5951929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528161A 2007-10-03 2008-10-03 Ｐｓｍａ抗体を用いる増殖性障害の治療 Active JP5951929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97736407P 2007-10-03 2007-10-03
US60/977,364 2007-10-03
PCT/US2008/078742 WO2009046294A2 (en) 2007-10-03 2008-10-03 Treatment of proliferative disorders using antibodies to psma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013207386A Division JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Division JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Publications (3)

Publication Number Publication Date
JP2010540657A JP2010540657A (ja) 2010-12-24
JP2010540657A5 true JP2010540657A5 (enExample) 2011-11-24
JP5951929B2 JP5951929B2 (ja) 2016-07-13

Family

ID=40404317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010528161A Active JP5951929B2 (ja) 2007-10-03 2008-10-03 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2013207386A Active JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Active JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013207386A Active JP5969446B2 (ja) 2007-10-03 2013-10-02 Ｐｓｍａ抗体を用いる増殖性障害の治療
JP2016005363A Active JP6054557B2 (ja) 2007-10-03 2016-01-14 Ｐｓｍａ抗体を用いる増殖性障害の治療

Country Status (5)

Country Link
US (4) US20100291113A1 (enExample)
EP (3) EP2209498A2 (enExample)
JP (3) JP5951929B2 (enExample)
CA (1) CA2700410C (enExample)
WO (1) WO2009046294A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
EP2817629A4 (en) * 2012-02-24 2016-01-13 Univ Cornell INCREASED PSMA VALUE AS IDENTIFIER OF DEADLY PROSTATE CANCER
CA2865774A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US20140099257A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability
MA41046A (fr) * 2014-10-10 2017-08-15 Memorial Sloan Kettering Cancer Center Thérapies liées au psma
EP3256495A4 (en) * 2015-02-11 2018-09-19 Aptevo Research and Development LLC Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
CN111801121B (zh) * 2017-04-11 2023-12-01 约翰霍普金斯大学 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
EP4146805A2 (en) * 2020-05-05 2023-03-15 ARO Biotherapeutics Company Prostate specific membrane antigen binding fibronectin type iii domains and cells comprising the same
JP2023532807A (ja) 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US6010902A (en) * 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US6197298B1 (en) * 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
DE4140142A1 (de) * 1991-12-05 1993-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim, De Multivalentes dextranreagenz zum einsatz in praezipitationstests
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
SG55079A1 (en) * 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
EP0812356B1 (en) * 1995-02-24 2006-02-08 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
GB9504344D0 (en) * 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP0977837A1 (en) * 1997-04-03 2000-02-09 Universite Laval Transgenic expression in genital tract and sexual accessory glands
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US5981209A (en) 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
ES2434961T5 (es) * 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP2080802B1 (en) * 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
EP1171468B1 (en) * 1999-04-09 2008-07-02 Universität Zürich Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
NZ517772A (en) * 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US6375991B1 (en) * 2000-09-08 2002-04-23 Albemarle Corporation Production of concentrated biocidal solutions
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU2002256505B2 (en) 2001-05-11 2008-06-26 Eisai Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
ATE535258T1 (de) * 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
EP2287186B1 (en) * 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005527474A (ja) * 2001-09-20 2005-09-15 コーネル リサーチ ファンデーション インコーポレーテッド 前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物
ES2559002T3 (es) * 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
ATE417858T1 (de) * 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
AU2003265235A1 (en) * 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
JP2004000045A (ja) * 2002-05-31 2004-01-08 Kyowa Hakko Kogyo Co Ltd 前立腺特異的膜抗原に対する抗体
AU2003278161A1 (en) * 2002-06-21 2004-01-06 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
US20050026178A1 (en) * 2003-03-28 2005-02-03 Marit Nilsen-Hamilton Allosteric probes and methods
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
PT3095793T (pt) * 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
JP4948174B2 (ja) * 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP1704228B1 (en) * 2004-01-16 2012-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
EP1718667B1 (en) * 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
EP1740954B1 (en) * 2004-04-07 2015-08-19 Genentech, Inc. Mass spectrometry of antibody conjugates
CA2563735C (en) * 2004-04-22 2020-07-14 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
EA010374B1 (ru) * 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) * 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006089231A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
ES2460517T3 (es) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2144930A1 (en) * 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
US7867483B2 (en) * 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
ES2547552T3 (es) * 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
JP6067222B2 (ja) * 2008-07-15 2017-01-25 ジェネンテック， インコーポレイテッド アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
BRPI0918587B1 (pt) * 2008-09-08 2020-10-13 Conocophillips Company processo e instalação para liquefazer um fluxo de gás natural
BRPI0919882A8 (pt) * 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
CN107254538A (zh) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
US20110020327A1 (en) * 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
JP5432132B2 (ja) * 2008-12-25 2014-03-05 東海ゴム工業株式会社 流体封入式防振装置
CN102459346B (zh) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
WO2011003171A1 (en) * 2009-07-08 2011-01-13 Smart Technologies Ulc Three-dimensional widget manipulation on a multi-touch panel
TWM383852U (en) * 2009-07-13 2010-07-01 Speedtech Corp An improvement of the universal serial bus connector
JPWO2011043061A1 (ja) * 2009-10-05 2013-03-04 キヤノン株式会社 光音響イメージング用造影剤、及び、それを用いた光音響イメージング方法

Similar Documents

Publication Publication Date Title
JP2010540657A5 (enExample)
Ratziu et al. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Forte et al. Obesity, diabetes, the cardiorenal syndrome, and risk for cancer
Matavelli et al. (Pro) renin receptor contributes to diabetic nephropathy by enhancing renal inflammation
JP6990170B2 (ja) Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
Saleh et al. Ibuprofen suppresses depressive like behavior induced by BCG inoculation in mice: role of nitric oxide and prostaglandin
JP2010515774A5 (enExample)
Zhang et al. Apelin attenuates depressive-like behavior and neuroinflammation in rats co-treated with chronic stress and lipopolysaccharide
JP2008520669A5 (enExample)
RU2587053C2 (ru) Комбинированная терапия и способ оценки невосприимчивости к лечению
CN116459250A (zh) 检测和治疗生长激素缺乏症
Paderni et al. Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects
Liu et al. AS-IV enhances the antitumor effects of propofol in NSCLC cells by inhibiting autophagy
Tang et al. Tetrahydroberberrubine exhibits preventive effect on obesity by activating PGC1α-mediated thermogenesis in white and brown adipose tissue
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Tiwari et al. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats
Huo et al. Ultrasound‐Guided Capsular Thyroid Injection Therapy With Dexamethasone and Lidocaine Mixture for Subacute Thyroiditis: A Single‐Center Study
Chawes et al. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol p MDI s in asthmatic children
JP2010510495A5 (enExample)
Egan et al. A randomized, single-blind, pharmacokinetic and doseresponse study of subcutaneous methotrexate, 15 and 25 MG/week, for refractory ulcerative colitis and Crohn's Disease
CN1921891B (zh) 连接到杯芳烃上的生长因子结合化合物
CN117327067B (zh) 一种小分子化合物epic-1042、药物组合物及其制备方法和应用
CN115837042B (zh) 当归补血汤在制备增强免疫检查点抑制剂疗效的药物中的应用
Gupta et al. Evidence based clinical study to assess the usefulness of homoeopathic medicines in patients of benign prostatic hyperplasia
Buch Clinically oriented pharmacology